NCT01033760 - Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

December 31, 2013

Conditions

HIV-1 Infections

Interventions

DRUG

raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine

raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.

DRUG

darunavir; ritonavir; emtricitabine/tenofovir

darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.

Trial Locations (1)

59208

Hôpital Gustave Dron, Tourcoing